Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 196,804,267 | 199,896,852 | 219,968,105 | 215,659,011 | 194,074,339 | 1,026,402,574 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 196,804,267 | 199,896,852 | 219,968,105 | 215,659,011 | 194,074,339 | 1,026,402,574 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 1,026,402,574 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 196,804,267 | 199,896,852 | 219,968,105 | 215,659,011 | 194,074,339 | 1,026,402,574 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 465,379 | 548,825 | 1,309,523 | 2,439,225 | 2,918,738 | 7,681,690 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 94,769 | 283,014 | 1,793,044 | 2,313,482 | 1,671,720 | 6,156,029 |
| 11 | Total support. Add lines 7 through 10 | 1,040,741,171 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2019 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2019 |
(iii) Distributable Amount for 2019 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2019 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2019: | ||||
| a From 2014....... | ||||
| b From 2015....... | ||||
| c From 2016....... | ||||
| d From 2017....... | ||||
| e From 2018....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2019 distributable amount | ||||
|
i
Carryover from 2014 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2019 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2019 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2019, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2019. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2020. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2015..... | ||||
| b Excess from 2016..... | ||||
| c Excess from 2017..... | ||||
| d Excess from 2018..... | ||||
| e Excess from 2019..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| PUBLIC DOCUMENTS | FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 The organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.JDRF.org. The public may access copies of JDRF's W-9, annual reports, 990 tax returns, 501(c)(3) IRS letter, and audited financials, at the following link: www.jdrf.org/about/financials |
| EXECUTIVE COMPENSATION POLICY | PART VI, SECTION B, LINES 15a & 15b JDRF's Board of Directors charges a Talent and Compensation Committee to develop and recommend a compensation philosophy that applies to all employees of JDRF, including recommendations regarding the compensation and benefits of JDRF senior management for approval by the Board of Directors. The Committee works in collaboration with the President and CEO and the Chief People Officer and other senior staff personnel in the JDRF Human Resources Department to ensure that 1) the Foundation's talent strategy supports and is aligned with its overall organization strategies; 2) JDRF is in compliance with IRS guidelines for determining reasonableness in pay practices; and 3) overall compensation for JDRF's key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of JDRF executive compensation and benefits under the procedures noted above is completed annually by an independent Compensation Committee, and the basis for their determination is documented contemporaneously in the minutes of the Committee's meetings, including most recently on June 30, 2020. |
| FORM 990 REVIEW PROCESS | SECTION B, PART VI, QUESTION 11B JDRF has a rigorous standard approach to reviewing its 990. The Organization's Senior Accountant works with its outside tax preparers to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including JDRF's Chief Financial Officer and AVP, FINANCE, the Chief Executive Officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft return are addressed. Following this process, the return is reviewed by JDRF's Audit Committee of the Board of Directors with its outside tax advisors. Once approved, the return is distributed to all members of JDRF's Board of Directors for review and comment before it is filed with the Internal Revenue Service. |
| PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS | LINE 4A ($68,847,301) RESEARCH GRANTS JDRF has played a significant role in nearly every T1D therapeutic advance made in the last 50 years. Our funding supports more than 500 active T1D research grants in the United States and 21 other countries around the world including more than 150 grants in 2020 alone, plus 75 clinical trials. We leverage partnerships with academia, industry and clinicians to accelerate the most promising research opportunities. Our highest priority is developing cures for T1D and improving lives of those living with the disease today, including research in glucose control and prevention of T1D complications. The full impact of JDRF's research investment extends well beyond direct funding. Through advocacy and influence, JDRF drives funding from other sources into the T1D research and has helped secure passage of the Special Diabetes Program, putting more than $3 billion in federal funding toward T1D research over the last two decades. In addition, JDRF founded the JDRF T1D Fund (www.t1dfund.org). The wholly owned subsidiary of JDRF, the Fund is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure T1D through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, pharma and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines to help people living with T1D or at risk of developing the disease. The T1D Fund invests in opportunities that drive our mission, with an exclusive focus on the best commercial opportunities. All funds go directly to support companies developing approaches to treat, prevent and cure T1D. In accordance with GAAP, $50MM of the T1D Fund's total investments as of June 30, 2020 are reflected in the Balance Sheet (Part X) and not included within the organization's research-related mission expense. The foundation's diversified research portfolio includes a focus on Curing T1D and Improving Lives. Curing T1D We face two key challenges in Curing T1D. We must prevent, stop or reverse: the loss of insulin-producing beta cells, and the immune systems attack on beta cells. JDRF is accelerating our work in Curing T1D by focusing on the two areas that have advanced dramatically over the last years: Beta Cell Therapies and Immune Therapies. Beta Cell Therapies: focus on replacing insulin-producing beta cells from outside sources and on internally regenerating and protecting existing beta cells. Through donor-funded research, we now know that when someone has T1D, their own body turns on itself, attacking and destroying the beta cells that create insulin. Understanding the role of beta cells -- was a breakthrough. If we can save beta cells, we can help cure T1D. Immune Therapies: focus on ways to keep the immune system from attacking and destroying beta cells, and to prevent the onset and advancement of T1D. Research has shown that immune therapies can interact with a persons immune system, training it to combat internal battles like cancer or autoimmune diseases like rheumatoid arthritis and T1D. While T1D remains one of the only major autoimmune diseases without an effective drug therapy, we know we are getting close. Improving Lives T1D brings with it daily struggles and stress that that make the challenges of living a healthy and long life with T1D very real. JDRF fights every day to advance research and technology that can reduce the burden of living with T1D and keep people as healthy as possible until we find cures. Specifically, we are striving to improve lives by driving research and work in Glucose Control Therapies and Complications Therapies which includes psychosocial well-being. Glucose Control Therapies: focus on helping those with T1D manage glucose levels and overall metabolic balance, including improved artificial pancreas technology, developing next-generation insulins and developing new drugs that control glucose in novel ways. We know that less than 30% of people with T1D in the U.S. consistently maintain target blood-glucose control levels meaning that 70% are at risk of serious health issues. Aiming to ensure our community is healthy when cures are found, we will continue our focus on bringing new innovation to this area, including improved artificial pancreas technology, next-generation insulins and new drugs that control glucose in novel ways. Complications Therapies: focus on accelerating therapies to prevent and treat kidney and eye disease and improving psychosocial well-being. We know that more than 90% of people with T1D develop eye disease within 20 years of diagnosis and that 1 in 4 develop kidney disease. We also know that prevalence of suicide is higher among young adults with T1D. Our focus on complications will be on accelerating therapies that prevent and treat kidney and eye disease. We also are expanding our support of psychosocial wellbeing. We have been supporting research of psychosocial wellbeing for several years. Now we are increasing our support as early research has shown that the burden of living with T1D takes a toll well beyond physical complications. Research also has shown us that young adults and teens with T1D are often impacted the most, with a significantly higher suicide rate. This is alarming and is our call to step up this work to help make a positive difference. LINE 4B ($16,997,889) RESEARCH SUPPORT JDRF's in-house team of skilled and credentialed scientific, policy and government relations professionals play critical roles in leading and supporting the research strategy and distribution of research funds from JDRF - and our partner organizations toward creating a world without T1D. Our professionals identify, evaluate and influence groundbreaking research for funding and work with other foundations, governments and industry to accelerate the mission we all share. JDRF professionals work with regulatory and policy officials to ensure research can proceed without delay and that advances are well understood by healthcare decision makers. As part of these efforts, JDRF organizes and funds scientific meetings, symposia, and conferences to review research proposals, ensure that JDRF's research strategy is aligned with the needs of the T1D community, and allow JDRF to provide scientific updates on the research it manages. This effort ensures that all the research is continually shared and built upon by T1D researchers around the globe. The Strategic Advisory Panel is composed of five established T1D experts in various aspects of the field, including pediatric endocrinology, prevention and treatment of T1D, immunotherapies, regulatory and drug development. The SAP contributes to JDRF scientists strategic planning around research funding goals and priorities. JDRF's work to bring together the best minds in the field enhances JDRF's ability to forecast future scientific direction, judge the potential effectiveness of new pathways, and identify gaps where JDRF funding can make the most impact. LINE 4C ($50,681,132) PUBLIC EDUCATION JDRF is uniquely qualified to provide public education about diabetes and its complications. JDRF's efforts impact not only the millions of people living with T1D, their families and the general public, but also those at risk for developing the disease. T1D strikes both children and adults suddenly, and the critical adjustment period following a diagnosis can be overwhelming. That's why we support families navigating this challenging time. JDRF also educates people about the warning signs of T1D, aimed at ensuring timely diagnoses and reducing the potential catastrophic consequences of undiagnosed T1D. JDRF also provides information and updates about current research directions and progress and about human clinical trials that are seeking participants (including through JDRF's Clinical Trials Connection matching tool: www.jdrf.org/research/clinical-trials). Through all of our national U.S. chapters; five international affiliates in Australia, Canada, Israel, the Netherlands and United Kingdom; the 30,000 members of our social network, TypeOneNation; and more than one million supports, JDRF fights to meet T1D community's diverse needs, connecting people with local support, expert resources, and the global effort to create a world without T1D. |
| CONFLICT OF INTEREST POLICY | FORM 990- PART VI-SECT B, LINE 12C All officers, directors, key employees, board and committee members (both chapters and international boards) are required to sign a conflict of interest policy annually and disclose any conflicts. The Office of the President and CEO manages this process, and JDRF's internal audit department annually audits to ensure compliance. If any conflict does arise, the board members with the conflicts will recuse themselves from the meeting and/or vote. |
| Software ID: | |
| Software Version: |